Lubumbashi

This registry collects detailed information about children diagnosed with cancer who are treated in pediatric oncology units affiliated with the French African Oncology Group in French-speaking Africa. Its goal is to gather data on patient numbers, cancer stage, treatments received, and outcomes to support better planning and delivery of pediatric oncology care in the region. The registry aims to provide valuable insights for local and national health authorities to improve pediatric cancer programs. Children and adolescents under 18 years old who present at participating pediatric oncology units and have any type of cancer are included in this observational registry. Data collected includes demographic information, socioeconomic status, clinical details, treatment status, vital status, treatment abandonment, and loss to follow-up. The information is entered online using the REDCap system and securely stored by the IT department at Gustave ROUSSY in Paris. Participants information is gathered continuously during their treatment and follow-up at the hospital units. The main measures tracked include the number of children suspected of having cancer within 12-month periods, their vital status, illness status, and treatment status. This ongoing data collection helps monitor outcomes and supports healthcare planning. Participation involves no experimental treatment and is focused on data recording and observation over time.

This research aims to improve treatment for children with Burkitts Lymphoma across at least 14 Sub Saharan countries, some new to this type of study. It focuses on earlier evaluation of children with stage I and II disease and earlier assessment of treatment response to decide if changes are needed. It also intends to intensify treatment for children with stage IV disease. Starting in 2026, the study will assess adding rituximab to current treatments and compare results with earlier implementations in two specific centers. The study involves observing the ability of treatment centers to follow the established GFA LMB2019 protocol for Burkitts Lymphoma. In two units, an amendment adds four rituximab injections during induction treatment, given on day 1 and day 6 of each induction cycle, depending on the risk group and treatment regimen. Other centers will continue using the original GFA LMB2019 treatment protocol without rituximab. Participants will be monitored over five years to evaluate the number of cases diagnosed with local disease and by stage, the treatments given, follow-up after treatment, and relapse rates. The study will also assess how well therapeutic recommendations are applied. This long-term observation helps understand treatment outcomes and the impact of adding rituximab in selected centers.

This research aims to evaluate how well treatment units follow therapeutic recommendations for children diagnosed with Nephroblastoma, a type of kidney cancer. It builds on two previous studies by the French Africa Pediatric Oncology Group GFAOP and focuses on treatment compliance and outcomes for children receiving care. The study also seeks to assess improvements in treatment adherence and reporting to better tailor future treatment programs to local conditions. The study involves children with suspected Nephroblastoma who receive standard care while clinical data are collected. Researchers will gather information on the clinical stage, treatments given, any treatment-related side effects, outcomes after treatment, and follow-up care. This observational study does not involve experimental treatments but monitors how existing protocols are applied and their results over time. Participants will be followed for up to five years, during which data on disease stage at diagnosis, treatment details, and follow-up visits will be recorded. The primary outcomes include the number of cases with localized and advanced disease, treatment regimens used, and compliance with follow-up care. Secondary outcomes examine reasons for treatment failure. This long-term monitoring helps understand treatment effectiveness and areas for improvement in care delivery.

This research aims to improve outcomes for children with retinoblastoma, a type of eye cancer, particularly in low-income African countries where survival rates are lower compared to high-income countries. The study focuses on children with stage II disease and hopes that early diagnosis and timely treatment can greatly enhance survival. This is an observational study designed to collect and analyze data on disease stage, treatments used, and patient outcomes over time. The study follows therapeutic recommendations for treating children diagnosed with retinoblastoma. It observes how well these treatment protocols are implemented and whether they lead to better survival rates. The study does not involve administering experimental treatments but monitors the treatments given according to these recommendations. Participants will be monitored and followed for up to 10 years to assess various outcomes, including the number of retinoblastoma cases at participating hospitals, the number of cases at stage II disease, the feasibility of applying these therapeutic recommendations in the African setting, and treatment evaluations. Follow-up care and data collection will support understanding the effectiveness and practicality of early diagnosis and treatment in improving survival.